Italia - italiano - Ministero della Salute

piam farmaceutici s.p.a. - metabolismo lipidico

Italia - italiano - Ministero della Salute

piam farmaceutici s.p.a. - metabolismo lipidico

Italia - italiano - Ministero della Salute

piam farmaceutici s.p.a. - metabolismo lipidico

Italia - italiano - Ministero della Salute

piam farmaceutici s.p.a. - metabolismo lipidico

Unione Europea - italiano - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosoppressori - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unione Europea - italiano - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosoppressori - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unione Europea - italiano - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosoppressori - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sanofi-aventis spa - dolasetron mesilato - preparazione iniettabile - iv 1 fiala 20 mg/ml 5 ml - prevenzione e trattamento della nausea e del vomito nei pazienti che ricevono un ciclo iniziale o cicli ripetuti di chemioterapia antiblastica (ivi incluso il cisplatino a dosi elevate). - trattamento della emesi post-operatoria. - prevenzione della emesi post-operatoria in pazienti ad alto rischio, come nella chirurgia ginecologica intraddominale o con all'anamnesi una storia di emesi post-operatoria.

Unione Europea - italiano - EMA (European Medicines Agency)

uniqure biopharma b.v.  - alipogene tiparvovec - iperlipoproteinemia tipo i - agenti modificanti i lipidi - glybera è indicato per pazienti adulti con diagnosi di carenza lipoproteica lipasi (lpld) familiare e affetto da attacchi di pancreatite grave o multipla nonostante le restrizioni di grasso nella dieta. la diagnosi di lpld deve essere confermata da test genetici. l'indicazione è limitata ai pazienti con livelli rilevabili di proteina lpl.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - acido ibandronico - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - farmaci per il trattamento delle malattie ossee - ibandronic acid è indicato negli adulti forprevention di eventi scheletrici (fratture patologiche, complicanze ossee che richiedono la radioterapia o della chirurgia) in pazienti con cancro al seno e metastasi ossee. il trattamento del tumore indotta ipercalcemia con o senza metastasi. trattamento dell'osteoporosi nelle donne in postmenopausa ad aumentato rischio di fratture (vedere paragrafo 5. una riduzione del rischio di fratture vertebrali è stata dimostrata l'efficacia su frattura del collo del femore non è stata stabilita.